During this call, we may make projections or other forward-looking statements regarding future events or the future financial performance of the Company. We’d like to caution you that those statements reflect our current expectations and that actual events or results may differ materially. We also like to refer you to Benchmark’s periodic reports that are filed from time-to-time with the Securities and Exchange Commission, including the Company’s 8-K and S4 filings, quarterly filings and Form 10-Q and our annual report on Form 10-K. These documents contain cautionary language and identify important risk factors which could cause actual results to differ materially from our projections or forward-looking statements. We undertake no obligation to update those projections or forward-looking statements in the future.Now, I will turn the call over to Cary. Cary Fu Thank you, Don. Good morning. Thank you for joining us on our call today. We are very pleased to share with you our results for the year 2010. Overall, 2010 was a very good year for Benchmark. We accomplished a revenue growth of about 15% when compared year 2010 to 2009. Along with the revenue growth, came earnings per shares growth about 52% on a year-over-year basis. We finished 2010 with a strong Q4. As you can recall through the last conference call, we expect some weakness from our computing customers in fourth quarter. However, the sales to the computing sector pick up late in the quarters were stronger than was originally anticipated. Along with these financial results for the year, Benchmark completed two of our strategic goals. Number one, medical Class III device capability in Asia. In November, we announced that our Thailand facility had been approved by FDA to manufacture Class III finished device on behalf of our large Tier one medical customers. This is a significant accomplishment that give us medical customers this capability everywhere around the globe.